Zhongnan Hospital

Company snapshot

Zhongnan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include CXCR4, Uterine Cervical Neoplasms. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zhongnan Hospital. Not investment advice.

• What is Zhongnan Hospital?

  Zhongnan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include CXCR4, Uterine Cervical Neoplasms. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov

• Is Zhongnan Hospital publicly traded?

  Zhongnan Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Zhongnan Hospital develop or market?

  We link 5 drug profile(s) where Zhongnan Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/zhongnan-hospital#company-drugs.

• What are the latest developments for Zhongnan Hospital?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Zhongnan Hospital focus on?

  Zhongnan Hospital focuses on CXCR4, Uterine Cervical Neoplasms based on our analysis of their pipeline programs and drug development activities.